Author

Haiying Zhang 1

1 Pfizer Inc,Collegeville, PA,United States

BASELINE ALBUMIN LEVEL IS NOT A SIGNIFICANT PREDICTOR OF TOFACITINIB EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF MULTIVARIATE EXPOSURE-RESPONSE ANALYSIS

Gary R. Lichtenstein, Andrew Tinsley, Xavier Roblin, Tadakazu Hisamatsu, Camille Vong, Shinichi Tsuchiwata, Konstantinos Tsilkos, Haiying Zhang, Arnab Mukherjee, Chinyu Su, David T. Rubin

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

Jean-Frederic Colombel, Walter Reinisch, Mark T. Osterman, Andrew J. Thorpe, Chudy I. Nduaka, Haiying Zhang, Nervin Lawendy, Gary S. Friedman, Chinyu Su

TOFACITINIB HAS INDUCTION EFFICACY IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, REGARDLESS OF PRIOR TNF INHIBITOR THERAPY

Geert R. D'Haens, Bruce E. Sands, William Sandborn, Toshifumi Hibi, Chinyu Su, Wojciech Niezychowski, Subrata Ghosh, Haiying Zhang, Dahong Yu, Deborah A. Woodworth, Paul Healey, Amy Marren, Julian Panés

TOFACITINIB FOR MAINTENANCE THERAPY IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS IN THE PHASE 3 OCTAVE SUSTAIN TRIAL: RESULTS BY LOCAL AND CENTRAL ENDOSCOPIC ASSESSMENTS

Brian G. Feagan, Severine Vermeire, William Sandborn, Walter Reinisch, Julian Panés, Dino Tarabar, Chinyu Su, Wojciech Niezychowski, Haiying Zhang, Gary S. Friedman, Deborah A. Woodworth, Bruce E. Sands

Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: an interim analysis of an open-label, long-term extension study with up to 5.5 years of treatment

Gary R. Lichtenstein, Edward V. Loftus Jr., Arif Soonasra, Nervin Lawendy, Gary Chan, Haiying Zhang, Wenjin Wang, Andrew J. Thorpe, Stuart Bloom

IMPROVEMENT IN PHYSICIAN'S GLOBAL ASSESSMENT WITHIN 2 WEEKS IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB

Michael Chiorean, David T. Rubin, Mark Lowenberg, Javier Gisbert, Konstantinos Tsilkos, Daniel Quirk, Leonardo Salese, Haiying Zhang, Deborah A. Woodworth, Chinyu Su

ONSET OF EFFICACY OF TOFACITINIB FOR INDUCTION THERAPY IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS IN TWO MULTINATIONAL, PHASE 3 CLINICAL TRIALS

William Sandborn, Silvio Danese, Julian Panés, Haiying Zhang, Deborah A. Woodworth, Amy Marren, Chinyu Su

TIME TO LOSS OF EFFICACY FOLLOWING TOFACITINIB INTERRUPTION IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM OCTAVE SUSTAIN

Marla C. Dubinsky, Kofi Clarke, Jochen G. Klaus, Yoram Bouhnik, Arif Soonasra, Andrew J. Thorpe, Haiying Zhang, Gary S. Friedman, Deborah A. Woodworth, Nervin Lawendy, Chinyu Su

TOFACITINIB FOR INDUCTION THERAPY IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS IN TWO PHASE 3 CLINICAL TRIALS: RESULTS BY LOCAL AND CENTRAL ENDOSCOPIC ASSESSMENTS

Brian G. Feagan, Severine Vermeire, Walter Reinisch, William Sandborn, Dino Tarabar, Wojciech Niezychowski, Chinyu Su, Haiying Zhang, Deborah A. Woodworth, Dahong Yu, Bruce E. Sands

TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY

Gary R. Lichtenstein, Edward V Loftus Jr, Stuart Bloom, Nervin Lawendy, Gary S. Friedman, Haiying Zhang, Wenjin Wang, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

Item 1 - 10 / 11
1
2